Genentech warns Lucentis eye drug carries risk of strokes

Genentech issued a letter to physicians warning its Lucentis drug for treating age-related macular degeneration may increase risk of stroke, particularly at high doses. The company called its cautionary letters to physicians a proactive step, but said the risks are in line with the drug's labeling.

View Full Article in:

NYTimes.com · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC